Opioid receptors and legal highs: Salvia divinorum and Kratom

Clinical Toxicology

Volumn 46, Issue 2, 2008, Pages 146-152

  Babu, Kavita M ^a   McCurdy, Christopher R ^b   Boyer, Edward W ^a,c  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Dietary supplements; Kratom; Mitragynine; Salvia divinorum; Salvinorin A

Indexed keywords

7 HYDROXYMITRAGYNINE; HERBACEOUS AGENT; MITRAGYNINE; OPIATE RECEPTOR; SALVINORIN A; UNCLASSIFIED DRUG;

ARTICLE; DIET SUPPLEMENTATION; DRUG ABUSE; DRUG DEPENDENCE; DRUG HALF LIFE; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; MITRAGYNA; NONHUMAN; SALVIA;

ANIMALS; DITERPENES; HUMANS; MOLECULAR STRUCTURE; PLANT PREPARATIONS; PSYCHOTROPIC DRUGS; RECEPTORS, OPIOID; RUBIACEAE; SALVIA; SECOLOGANIN TRYPTAMINE ALKALOIDS;

MITRAGYNA SPECIOSA; SALVIA DIVINORUM;

EID: 38949213304     PISSN: 15563650     EISSN: 15569519     Source Type: Journal    
DOI: 10.1080/15563650701241795     Document Type: Article

References (49)

1. Dennehy CE, Tsourounis C, Miller AE. Evaluation of herbal dietary supplements marketed on the internet for recreational use. Ann Pharmacother 2005; 39(10):1634-9.
2. Ethnosupply.com.Available at 〈http://www.ethnosupply.com/store/ salvia-freshman-package.html〉 Accessed January 2, 2007.
3. Prisinzano TE. Psychopharmacology of the hallucinogenic sage Salvia divinorum. Life Sci 2005; 78(5):527-31.
4. Salviasupply.com. Available at 〈http://www.salviasupply.com/store/ salvia-freshman-package.html〉 Accessed January 2, 2007.
5. Boyer EW, Shannon M, Hibberd PL. The Internet and psychoactive substance use among innovative drug users. Pediatrics 2005; 115(2):302-5.
6. A Legal High. Available at 〈http://www.ithaca.edu/ithacan/articles/ 0409/23/news/LSa_legal_high.htm〉 Accessed March 6, 2006.
7. Drugs and chemicals of concern: Salvia Divinorum. Drug Enforcement Administration, 2002. Available at 〈http://www.deadiversion.usdoj.gov/ drugs_concern/salvia_d/summary.htm〉 Accessed November 11, 2004.
8. Herbal Smoke and Legal Bud Shop. (http://iamshamanshop.com/). (2 Januaey 2007).
9. The Salvia Divinorum Research and Information Center. Available at 〈http://www.sagewisdom.org/salviashop.html〉 Accessed January 2, 2007.
10. Shaw L. The Clinical Toxicology Laboratory: Contemporary Practice of Poisoning Evaluation. Washington DC: AACC Press, 2001.
11. Erowid Salvia Vault. Available at 〈http://www.erowid.org/plants/ salvia/salvia_testing.shtml〉January 2, 2006.
12. Tidgewell K, Harding WW, Schmidt M, Holden KG, Murry DJ, Prisinzano TE. A facile method for the preparation of deuterium labeled salvinorin A: Synthesis of [2,2,2-2H3]-salvinorin A. Bioorg Med Chem Lett 2004; 14(20):5099-102.
13. Bucheler R, Gleiter CH, Schwoerer P, Gaertner I. Use of nonprohibited hallucinogenic plants: increasing relevance for public health? A case report and literature review on the consumption of Salvia divinorum (Diviner's Sage). Pharmacopsychiatry 2005; 38(1):1-5.
14. Dorell O. Powerful but legal hallucinogenic under scrutiny. Available at 〈http://www.usatoday.com/news/nation/2006-04-02-salvia_x.htm〉 Accessed on December 15, 2006.
15. Drugs and Chemicals of Concern: Salvia Divinorum. Available at 〈http://www.deadiversion.usdoj.gov/drugs_concern/salvia_d/salvia_d. htm〉Accessed January 2, 2007.
16. Boyer EW, Shannon M, Hibberd P. The Internet and psychoactive substance use among innovative drug users. Pediatrics 2005; 115:302-5.
17. "Salvia divinorum/ Maria Pastora" keyword search for 2000-2005. American Association of Poison Control Centers database. Conducted April 26, 2006.
18. Yan F, Roth BL. Salvinorin A: A novel and highly selective kappa-opioid receptor agonist. Life Sci 2004; 75:2615-9.
19. McCurdy CR, Sufka KJ, Smith GH, Warnick JE, Nieto MJ. Antinociceptive profile of salvinorin A, a structurally unique kappa opioid receptor agonist. Pharmacol Biochem Behav 2006; 83(1):109-13.
20. Harding WW, Tidgewell K, Byrd N, Cobb H, Dersch CM, Butelman ER, Rothmann RB, Prisinzano TE. Neoclerodane diterpenes as a novel scaffold for mu opioid receptor ligands. J Med Chem 2005; 48(15):4765-71.
21. Capasso R, Borrelli F, Capasso F, Siebert DJ, Stewart DJ, Zjawiony JK, Izzo AK. The hallucinogenic herb Salvia divinorum and its active ingredient salvinorin A inhibit enteric cholinergic transmission in the guinea-pig ileum. Neurogastroenterol Motil 2006; 18(1):69-75.
22. Fantegrossi WE, Kugle KM, Valdes LJ, 3rd, Koreeda M, Woods JH. Kappa-opioid receptor-mediated effects of the plant-derived hallucinogen, salvinorin A, on inverted screen performance in the mouse. Behav Pharmacol 2005; 16(8):627-33.
23. Zhang Y, Butelman ER, Schlussman SD, Ho A, Kreek MJ. Effects of the plant-derived hallucinogen salvinorin A on basal dopamine levels in the caudate putamen and in a conditioned place aversion assay in mice: agonist actions at kappa opioid receptors. Psychopharmacology (Berl) 2005; 179(3):551-8.
24. Carlezon WA, Jr., Beguin C, DiNieri JA, Baumann MH, Richards MR, Todtenkopf MS, Rothman RB, Ma Z, Lee DY-W, Cohen BM. Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats. J Pharmacol Exp Ther 2006; 316(1):440-7.
25. Roth BL, Baner K, Westkaemper R, Siebert D, Rice KC, Steinberg S, Ernsberger P, Rothman RB. Salvinorin A: A potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proc Natl Acad Sci USA 2002; 99(18):11934-9.
26. Hanes KR. Antidepressant effects of the herb Salvia divinorum: A case report. J Clin Psychopharmacol 2001; 21(6):634-5.
27. Siebert DJ. Salvia divinorum and salvinorin A: New pharmacologic findings. J Ethnopharmacol 1994; 43:53-6.
28. Schmidt M, Schmidt M, Butelman E, et al. Pharmokinetics of the Plant-Derived k-Opioid Hallucinogen Salvinorin A in Nonhuman Primates. Synapse 2005; 58:208-10.
29. Schmidt MS, Prisinzano TE, Tidgewell K, et al. Determination of Salvinorin A in body fluids by high performance liquid chromatography- atmospheric pressure chemical ionization. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 818(2):221-5.
30. Halpern JH. Hallucinogens and dissociative agents naturally growing in the United States. Pharmacol Ther 2004; 102:131-8.
31. Pichini S, Abanades S, Farre M, et al. Quantification of the plantderived hallucinogen Salvinorin A in conventional and non-conventional biological fluids by gas chromatography/mass spectrometry after Salvia divinorum smoking. Rapid Commun Mass Spectrom 2005; 19(12):1649-56.
32. Shellard EJ. Ethnopharmacology of kratom and the Mitragyna alkaloids. J Ethnopharmacol 1989; 25(1):123-4.
33. Grewal K. Observation on the pharmacology of mitragynine. J Pharmacology and Experimental Therapeutics 1932; 46:251-71.
34. Suwanlert S.A study of kratom eaters in Thailand. Bull Narc 1975; 27(3):21-7.
35. National Drug Intelligence Center. Herbal Drug Update: Kratom. Narcotics Digest Weekly 2005; 4(16):4.
36. "Mitragyna speciosa" keyword search for 2000-2005. American Association of Poison Control Centers database. Conducted April 26, 2006.
37. Boyer E, Babu K, Macalino G, Compton W. Self-treatment of opioid withdrawal with a dietary supplement, Kratom. Am J Addictions 2007; 16(5):352-356.
38. Drugbuyers.com. Available at 〈http://www.drugbuyers.com〉 Accessed January 4, 2006.
39. PsychoactiveHerbs. Available at 〈http://psychoactiveherbs.com/ catalog〉 Accessed October 10, 2006.
40. Shellard E. The alkaloids of Mitragyna with special reference. Bull Narc 1974; 26(2):41-55.
41. Yamamoto LT, Horie S, Takayama H, Aimi N, Sakai S, Yano S, Shan J, Pang PK, Ponglux D, Watandoe K. Opioid receptor agonistic characteristics of mitragynine pseudoindoxyl in comparison with mitragynine derived from Thai medicinal plant Mitragyna speciosa. Gen Pharmacol 1999; 33(1):73-81.
42. Thongpradichote S, Matsumoto K, Tohda M, Takayama H, Aimi N, Sakai S, Watanabe H. Identification of opioid receptor subtypes in antinociceptive actions of supraspinally-administered mitragynine in mice. Life Sci 1998; 62(16):1371-8.
43. Matsumoto K, Suchitra T, Murakami Y, Takayama H, Sakai S, Aimi N, Watanabe H. Central antinociceptive effects of mitragynine in mice: Contribution of descending noradrenergic and serotonergic systems. Eur J Pharmacol 1996; 317:75-81.
44. Matsumoto K, Yamamoto LT, Watanabe K, Yano S, Shan J, Pang PK, Ponglux D, Takayama H, Horie S. Inhibitory effect of mitragynine, an analgesic alkaloid from Thai herbal medicine, on neurogenic contraction of the vas deferens. Life Sci 2005.
45. Matsumoto K, Horie S, Ishikawa H, Takayama H, Aimi N, Ponglux D, Watanabe K. Antinociceptive effect of 7-hydroxymitragynine in mice: Discovery of an orally active opioid analgesic from the Thai medicinal herb Mitragyna speciosa. Life Sci 2004; 74(17):2143-55.
46. Jansen KL, Prast CJ. Psychoactive properties of mitragynine (kratom). J Psychoactive Drugs 1988; 20(4):455-7.
47. Macko E, Weisbach JA, Douglas B. Some observations on the pharmacology of mitragynine. Arch Int Pharmacodyn Ther 1972; 198(1):145-61.
48. Thuan LC. Addiction to Mitragyna Speciosa. Proceeding of the Alumni Association, Malaya 1957; 10(4):322-4.
49. Takayama H. Chemistry and pharmacology of analgesic indole alkaloids from the rubiaceous plant, Mitragyna speciosa. Chem Pharm Bull (Tokyo) 2004; 52(8):916-28.